Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences >

Biotech Values

RSS Feed
      Hide Sticky   Hide Intro
Moderator: DewDiligence Assistants: Biowatch
Search This Board:
Last Post: 11/1/2014 1:13:33 AM - Followers: 1119 - Board type: Free - Posts Today: 2
PostSubject
#183398  Sticky Note The Fibrogen presentation is up on retailroadshow: biomaven0 10/31/14 11:27:19 AM
#183392  Sticky Note ABBV spending on anticipated HCV launch (from 3Q14 PR): DewDiligence 10/31/14 08:17:55 AM
#183389  Sticky Note SGEN report was well received by the pre-market. ilpapa 10/31/14 06:11:22 AM
#183380  Sticky Note SRPT I don't think we should be too iwfal 10/30/14 06:57:51 PM
#183379  Sticky Note Re: SRPT: poorgradstudent 10/30/14 06:22:01 PM
#183072  Sticky Note https://twitter.com/DewDiligence/status/524721036626251777 DewDiligence 10/21/14 08:38:48 PM
#183413   SRPT RNA FDA - random bizarre thought suitable iwfal 11/01/14 01:13:33 AM
#183412   >Fibrogen In terms of safety, there have been over biomaven0 11/01/14 12:23:02 AM
#183411   >The Fibrogen presentation is up on retailroadshow: kiroset 10/31/14 08:58:20 PM
#183410   Adherex changed their name to Fennec Pharma... DFRAI 10/31/14 04:23:22 PM
#183409   Does anyone follow cadherin research?I haven’t followed th DewDiligence 10/31/14 03:48:08 PM
#183408   Does anyone follow cadherin research? TIA DFRAI 10/31/14 03:32:45 PM
#183406   Thanks Blade DFRAI 10/31/14 03:11:31 PM
#183405   re: ARQL bladerunner1717 10/31/14 02:55:59 PM
#183404   Anything exciting in those posters? DFRAI 10/31/14 02:50:38 PM
#183403   SGEN Nothing in the report really took me by surprise dewophile 10/31/14 02:43:18 PM
#183402   EORTC--November 18-21 in Barcelona bladerunner1717 10/31/14 02:10:30 PM
#183401   The HCV franchise will help diversify sales but dewophile 10/31/14 01:52:10 PM
#183399   EXAS—Non-Medicare patients will have to pay $50 up-front DewDiligence 10/31/14 12:27:33 PM
#183398   The Fibrogen presentation is up on retailroadshow: biomaven0 10/31/14 11:27:19 AM
#183397   addendum... biocqr 10/31/14 10:41:04 AM
#183396   Checkpoint inhibitors (h/t @zDonShimoda)... biocqr 10/31/14 10:31:55 AM
#183395   >>CMRX sells 4.2M shares @$29.00 biomaven0 10/31/14 10:22:47 AM
#183394   I did ask my nephew about this (he's biomaven0 10/31/14 10:19:33 AM
#183393   3Q14 Humira sales reached annualized rate of $13.0B, DewDiligence 10/31/14 09:16:59 AM
#183392   ABBV spending on anticipated HCV launch (from 3Q14 PR): DewDiligence 10/31/14 08:17:55 AM
#183391   MDVN/Astellas are seeking to hasten change in the DewDiligence 10/31/14 07:02:42 AM
#183390   Yes, that’s a computer-generated newswire by AP/Zacks. Caveat DewDiligence 10/31/14 07:00:13 AM
#183389   SGEN report was well received by the pre-market. ilpapa 10/31/14 06:11:22 AM
#183388   i think people also forget that $srpt is masterlongevity 10/30/14 08:58:11 PM
#183387   SRPT: ive met with the FDA many times. they poorgradstudent 10/30/14 08:28:18 PM
#183386   ABT’s CEO, Miles White, exercised and sold $18.7M DewDiligence 10/30/14 08:23:56 PM
#183385   $SRPT masterlongevity 10/30/14 08:09:25 PM
#183384   $SRPT. I am glad they replied. masterlongevity 10/30/14 08:04:00 PM
#183383   SRPT: At this instant, yes. But in an AdCom poorgradstudent 10/30/14 07:55:00 PM
#183382   SRPT Never seen the FDA (or any other iwfal 10/30/14 07:10:30 PM
#183381   CMRX sells 4.2M shares @$29.00—an 8% discount to DewDiligence 10/30/14 07:00:02 PM
#183380   SRPT I don't think we should be too iwfal 10/30/14 06:57:51 PM
#183379   Re: SRPT: poorgradstudent 10/30/14 06:22:01 PM
#183378   FDA replies to SRPT’s 10/27/14 PR: DewDiligence 10/30/14 06:13:18 PM
#183377   FDA advisory panel endorses Edoxaban for AF/stroke prevention DewDiligence 10/30/14 05:49:30 PM
#183376   MEIP advances mitochondrial inhibitor in various solid tumors bladerunner1717 10/30/14 05:10:36 PM
#183375   >>Medicare sans Part D biomaven0 10/30/14 04:58:46 PM
#183374   Re Big Cap Bio - continued incredible performance. Rocky3 10/30/14 04:13:29 PM
#183373   BMY—Make that +9% today;new 13-year high. DewDiligence 10/30/14 04:06:21 PM
#183372   Affinivax (private) seeks slice of PFE’s Prevnar franchise: DewDiligence 10/30/14 03:59:27 PM
#183371   I should have asked about Medicare sans Part D. DewDiligence 10/30/14 03:50:18 PM
#183370   >>unexplained impetuses for Medicare cost reduction biomaven0 10/30/14 03:15:11 PM
#183369   I haven't gone through NVO 3Q2014 result yet. jq1234 10/30/14 01:43:25 PM
#183368   So, there are unexplained impetuses for Medicare cost DewDiligence 10/30/14 12:28:58 PM
#183367   (AMGN/NVS)—Neupogen FoB case illustrates complexity of 351(k) patent-exchange process: DewDiligence 10/30/14 12:25:53 PM
#183366   CEMP Third Quarter 2014 Financial Results mr_o 10/30/14 11:29:35 AM
#183365   NVO may opt to conduct a new Treshiba DewDiligence 10/30/14 10:45:25 AM
#183364   BAX high-concentration sub-Q IG meets primary endpoint in DewDiligence 10/30/14 10:43:10 AM
#183363   BMY +5% on phase-2 Opdivo date in NSCLC: DewDiligence 10/30/14 10:38:20 AM
#183362   INGN insiders sold 2.4M* shares @$21.50—a 3% discount DewDiligence 10/30/14 10:32:09 AM
PostSubject